Safety and Efficacy of Using CBUS™ System for Ultrasound Breast Imaging Designed for Breast Tumor Diagnosis

Breast Cancer Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00355745
• Other study ID #: CBUS -RA-001
• Status: Terminated
• Phase: N/A
• First received: July 22, 2006
• Last updated: June 8, 2011
• Start date: July 2006
• Est. completion date: July 2009

Study information

• Verified date: May 2008
• Source: Helix Medical Systems
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: The Israel National Institute for Health Policy Research and Health Services Research
• Study type: Interventional

Clinical Trial Summary

In the United States, breast cancer is the most common cancer occurring in women (excluding cancers of the skin) and the second most common cause of death from cancer in women (after lung cancer). Approximately 182,800 new cases per year occur in the United States, causing 40,800 death cases per year. Breast cancer is the leading cause of death in women aged 44-50 years. The 5-year survival rate is 60% overall but is greater than 80% for early disease.

If diagnosed at an early stage, breast cancer has an encouraging cure rate: up to 97% of women diagnosed with localized breast cancer will survive five years after their diagnosis. Even if the cancer is found at a more advanced stage, new therapies have enabled many people with breast cancer to experience the same quality of life as before their diagnosis.

Breast ultrasound (US) is an extremely useful modality in the diagnosis of breast disease in the symptomatic clinic. It is routinely used as an adjunct to x-ray mammography and clinical examination and, with younger patients it may be the sole imaging modality. It has well-established value in differentiating between malignant and benign solid lesions in some cases, however, it cannot replace fine needle aspiration and core biopsy.

Conventional breast US scanning is highly operator- dependent, requiring skillful probe manipulation and the mental ability to envisage 3-D tissue structure. Acquiring 3-D US data sets may be advantageous, making it easier to see and interpret 3-D structures, boundaries and interactions.

CBUS™, Circular Breast Ultrasound Scanner is indicated to improve significantly breast images obtained by ultrasound systems. The CBUS™ system automatically acquires a complete breast image and constructs a high quality 3D image of the scanned breast. These images provide diagnostic information of the complete volume of breast tissue including blood flow in a single ultrasonic 3D image.

In this clinical study, the CBUS™ Circular Breast Ultrasound Scanner will be used to automatically image the complete breast and provides a high quality 3D image of the scanned breast.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 50
• Est. completion date: July 2009
• Est. primary completion date: December 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 21 Years to 70 Years

Eligibility

Inclusion Criteria:

• Female age between 21-70 years.

• Subject has mammography or ultrasound findings

• Subject is scheduled for biopsy.

• Subject is scheduled for ultrasound breast scan.

• Subject understands the study procedure.

• Subject is willing to sign the inform consent and comply with the study requirements.

Exclusion Criteria:

• Age < 21 years or > 70 years.

• Subject undergo previous breast surgery

• Known blood coagulation disorders.

• Known cardiac disorders.

• Breast infection / breast abscess / breast pains.

• Ipsilateral breast scar in same quadrant as current lesion

• Recent breast trauma.

• Pregnant or lactating woman

• Subject has bleeding disorder.

• Subject is suffering extreme general weakness.

• Subject objects to the study protocol.

• Physician objection.

• Known cognitive or psychiatric disorder

• Participation in any other clinical trial

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Breast Cancer

Intervention

Device:
• Ultrasound breast scanning
breast scanning

Locations

Country	Name	City	State
Israel	RAMBAM Medical Center	Haifa

Sponsors (1)

Lead Sponsor	Collaborator
Helix Medical Systems

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrences of adverse events		immediately	Yes
Secondary	Quality of ultrasound imaging		within 1 day	No